UBS maintains a 'Buy' on Biogen (NASDAQ: BIIB) price target of $156.00 (from $148.00).

Analyst, Matthew Roden, said, "(1) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE